NASDAQ:ICCC - ImmuCell Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$7.12 +0.12 (+1.71 %)
(As of 02/20/2019 06:27 AM ET)
Previous Close$7.00
Today's Range$7.12 - $7.12
52-Week Range$6.38 - $9.30
Volume200 shs
Average Volume5,162 shs
Market Capitalization$39.09 million
P/E RatioN/A
Dividend YieldN/A
Beta1.28
ImmuCell Corporation, an animal health company, develops, acquires, manufactures, and sells products that enhance the health and productivity of dairy and beef cattle in the United States and internationally. The company primarily offers First Defense, an orally delivered scours preventive product for newborn calves. It also provides California Mastitis Test, which is used to detect somatic cell counts in milk, as well as to determine, which quarter of the udder is mastitic. In addition, the company is involved in developing purified Nisin treatment for subclinical mastitis in lactating dairy cows; and selling various product applications of its First Defense Technology, including a whey protein concentrate for the nutritional and feed supplement markets. ImmuCell Corporation sells its products to animal health distributors, fleet stores, and direct to farms. The company was founded in 1982 and is headquartered in Portland, Maine.

Receive ICCC News and Ratings via Email

Sign-up to receive the latest news and ratings for ICCC and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Diagnostic substances
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:ICCC
CUSIPN/A
Phone207-878-2770

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$10.99 million
Cash Flow$0.1360 per share
Book Value$4.31 per share

Profitability

Net Income$-2,320,000.00

Miscellaneous

Employees47
Market Cap$39.09 million
OptionableNot Optionable

ImmuCell (NASDAQ:ICCC) Frequently Asked Questions

What is ImmuCell's stock symbol?

ImmuCell trades on the NASDAQ under the ticker symbol "ICCC."

How were ImmuCell's earnings last quarter?

ImmuCell Co. (NASDAQ:ICCC) issued its quarterly earnings results on Wednesday, February, 13th. The biotechnology company reported ($0.19) EPS for the quarter. The biotechnology company earned $2.94 million during the quarter. ImmuCell had a negative net margin of 21.13% and a negative return on equity of 7.65%. View ImmuCell's Earnings History.

When is ImmuCell's next earnings date?

ImmuCell is scheduled to release their next quarterly earnings announcement on Monday, May 13th 2019. View Earnings Estimates for ImmuCell.

Has ImmuCell been receiving favorable news coverage?

News articles about ICCC stock have trended somewhat positive recently, InfoTrie reports. The research firm ranks the sentiment of news coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. ImmuCell earned a media sentiment score of 1.7 on InfoTrie's scale. They also gave news articles about the biotechnology company a news buzz of 10.0 out of 10, meaning that recent news coverage is extremely likely to have an impact on the stock's share price in the near term.

Who are some of ImmuCell's key competitors?

Who are ImmuCell's key executives?

ImmuCell's management team includes the folowing people:
  • Mr. Michael F. Brigham, Pres, CEO, Treasurer, Sec. & Director (Age 58)
  • Dr. Joseph H. Crabb, VP & Chief Scientific Officer (Age 64)
  • Ms. Bobbi Jo Brockmann, VP of Sales & Marketing and Director (Age 42)
  • Ms. Elizabeth L. Williams, VP of Manufacturing Operations (Age 63)
  • Mr. A. Gustavo Scaffa, Sr. Director of Quality

Who are ImmuCell's major shareholders?

ImmuCell's stock is owned by many different of retail and institutional investors. Top institutional investors include Essex Financial Services Inc. (0.38%). Company insiders that own ImmuCell stock include Brian L Pessin and David Scott Tomsche. View Institutional Ownership Trends for ImmuCell.

Which major investors are selling ImmuCell stock?

ICCC stock was sold by a variety of institutional investors in the last quarter, including Essex Financial Services Inc.. View Insider Buying and Selling for ImmuCell.

How do I buy shares of ImmuCell?

Shares of ICCC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is ImmuCell's stock price today?

One share of ICCC stock can currently be purchased for approximately $7.12.

How big of a company is ImmuCell?

ImmuCell has a market capitalization of $39.09 million and generates $10.99 million in revenue each year. ImmuCell employs 47 workers across the globe.

What is ImmuCell's official website?

The official website for ImmuCell is http://www.immucell.com.

How can I contact ImmuCell?

ImmuCell's mailing address is 56 EVERGREEN DR, PORTLAND ME, 04103. The biotechnology company can be reached via phone at 207-878-2770 or via email at [email protected]


MarketBeat Community Rating for ImmuCell (NASDAQ ICCC)

Community Ranking:  3.0 out of 5 (star star star)
Outperform Votes:  96 (Vote Outperform)
Underperform Votes:  66 (Vote Underperform)
Total Votes:  162
MarketBeat's community ratings are surveys of what our community members think about ImmuCell and other stocks. Vote "Outperform" if you believe ICCC will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ICCC will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/20/2019 by MarketBeat.com Staff

Featured Article: What is the Bid-Ask Spread?

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel